Molecular Templates (Molecular Templates) Net Change in Cash

: $-12.73 Mil (TTM As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Molecular Templates's Net Change in Cash for the three months ended in Dec. 2023 was $-5.29 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was $-12.73 Mil.

Molecular Templates Net Change in Cash Historical Data

The historical data trend for Molecular Templates's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Templates Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

0.73

-59.57

-0.23

6.03

-21.84

Molecular Templates Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Change in Cash																9.91	6.59	-6.50	-7.53	-5.29

Molecular Templates Net Change in Cash Calculation

Molecular Templates's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-41.82	+	29.095	+	-9.116	+	0
	=	-21.84

Molecular Templates's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -5.287 + -0.001 + 0 + 0

= -5.29

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Molecular Templates Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Molecular Templates's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Molecular Templates (Molecular Templates) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Templates Inc (NAS:MTEM) » Definitions » Net Change in Cash

Comparable Companies

INTI CLCS ELAB ZEOX PRTG ERNA FRES MBIO EDSA BCDA OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX

Traded in Other Exchanges

N/A

Address

9301 Amberglen Boulevard, Suite 100, Austin, TX, USA, 78729

Website

https://www.mtem.com

Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer.

Executives

Maurizio Voi officer: Chief Medical Officer 4 MAGUIRE ROAD, LEXINGTON MA 02421

Biotech Target N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000

Sean Mclennan officer: CFO & Treasurer C/O MOLECULAR TEMPLATES, INC., 93010 AMBERGLEN BLVD., SUITE 100, AUSTIN TX 78729

Kevin M. Lalande director, 10 percent owner 201 WEST 5TH STREET, AUSTIN TX 78701

Shv Management Services, Llc 10 percent owner FROST TOWER, 401 CONGRESS AVENUE, SUITE 2950, AUSTIN TX 78701

Gabriela Gruia director C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451

Jason S. Kim officer: See Remarks 9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729

Biotech Ag Bb 10 percent owner SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200

Longitude Capital Partners Iii, Llc 10 percent owner 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025

Sanders Corazon (corsee) D. director C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729

Patrick G Enright 10 percent owner CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025

Bakker Juliet Tammenoms 10 percent owner LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025

David Hirsch director, 10 percent owner C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025

Longitude Venture Partners Iii, L.p. 10 percent owner 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025

Scott D Morenstein director C/O CAXTON ALTERNATIVE MANAGEMENT LP, 1330 SIXTH AVENUE, 20TH FLOOR, NEW YORK NY 10019

Molecular Templates (Molecular Templates) Headlines

From GuruFocus

Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
By GlobeNewswire GlobeNewswire • 05-26-2023

Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI's 5th Annual HealthCONx Conference and Piper Sandler's 34th Annual Healthcare Conference
By Value_Insider Value_Insider • 11-23-2022

Molecular Templates, Inc. Reports First Quarter 2022 Financial Results
By GuruFocusNews GuruFocusNews • 07-01-2022

Molecular Templates to Present at Upcoming Investor Conferences
By GuruFocusNews GuruFocusNews • 06-16-2022

Molecular Templates, Inc. Reports First Quarter 2022 Financial Results
By GuruFocusNews GuruFocusNews • 06-21-2022

Molecular Templates Announces Participation in Upcoming Conferences
By sperokesalga sperokesalga • 03-01-2023

Molecular Templates' Presentations at the 2022 ASCO Annual Meeting Demonstrate Advancement in PD-L1 and HER2 Programs
By GuruFocusNews GuruFocusNews • 06-26-2022

Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma
By sperokesalga sperokesalga • 06-01-2023

Molecular Templates Announces Participation in Four Upcoming Conferences
By Ds*** Ds*** • 08-31-2022

Molecular Templates, Inc. Reports First Quarter 2022 Financial Results
By GuruFocusNews GuruFocusNews • 06-11-2022

Maurizio Voi	officer: Chief Medical Officer	4 MAGUIRE ROAD, LEXINGTON MA 02421
Biotech Target N V	10 percent owner	ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Sean Mclennan	officer: CFO & Treasurer	C/O MOLECULAR TEMPLATES, INC., 93010 AMBERGLEN BLVD., SUITE 100, AUSTIN TX 78729
Kevin M. Lalande	director, 10 percent owner	201 WEST 5TH STREET, AUSTIN TX 78701
Shv Management Services, Llc	10 percent owner	FROST TOWER, 401 CONGRESS AVENUE, SUITE 2950, AUSTIN TX 78701
Gabriela Gruia	director	C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Jason S. Kim	officer: See Remarks	9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729
Biotech Ag Bb	10 percent owner	SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Longitude Capital Partners Iii, Llc	10 percent owner	800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Sanders Corazon (corsee) D.	director	C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729
Patrick G Enright	10 percent owner	CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Bakker Juliet Tammenoms	10 percent owner	LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
David Hirsch	director, 10 percent owner	C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Longitude Venture Partners Iii, L.p.	10 percent owner	800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Scott D Morenstein	director	C/O CAXTON ALTERNATIVE MANAGEMENT LP, 1330 SIXTH AVENUE, 20TH FLOOR, NEW YORK NY 10019